These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29196024)

  • 1. Poly(methyl vinyl ether-co-maleic acid) for enhancement of solubility, oral bioavailability and anti-osteoporotic effects of raloxifene hydrochloride.
    Varshosaz J; Minaiyan M; Dayyani L
    Eur J Pharm Sci; 2018 Jan; 112():195-206. PubMed ID: 29196024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced solubility, oral bioavailability and anti-osteoporotic effects of raloxifene HCl in ovariectomized rats by Igepal CO-890 nanomicelles.
    Varshosaz J; Ziaei V; Minaiyan M; Jahanian-Najafabadi A; Sayed-Tabatabaei L
    Pharm Dev Technol; 2019 Feb; 24(2):133-144. PubMed ID: 29338533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Production of a new platform based on fumed and mesoporous silica nanoparticles for enhanced solubility and oral bioavailability of raloxifene HCl.
    Varshosaz J; Dayani L; Chegini SP; Minaiyan M
    IET Nanobiotechnol; 2019 Jun; 13(4):392-399. PubMed ID: 31171744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of a transdermal formulation containing raloxifene nanoparticles for osteoporosis treatment.
    Nagai N; Ogata F; Otake H; Nakazawa Y; Kawasaki N
    Int J Nanomedicine; 2018; 13():5215-5229. PubMed ID: 30233182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifunctional Poly(methyl vinyl ether-co-maleic anhydride)-graft-hydroxypropyl-β-cyclodextrin Amphiphilic Copolymer as an Oral High-Performance Delivery Carrier of Tacrolimus.
    Zhang D; Pan X; Wang S; Zhai Y; Guan J; Fu Q; Hao X; Qi W; Wang Y; Lian H; Liu X; Wang Y; Sun Y; He Z; Sun J
    Mol Pharm; 2015 Jul; 12(7):2337-51. PubMed ID: 26024817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A matrix dispersion based on phospholipid complex system: preparation, lymphatic transport, and pharmacokinetics.
    Li H; Lu S; Luo M; Li X; Liu S; Zhang T
    Drug Dev Ind Pharm; 2020 Apr; 46(4):557-565. PubMed ID: 32126844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis.
    Saini D; Fazil M; Ali MM; Baboota S; Ali J
    Drug Deliv; 2015; 22(6):823-36. PubMed ID: 24725026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(vinyl methyl ether/maleic anhydride)-Doped PEG-PLA Nanoparticles for Oral Paclitaxel Delivery To Improve Bioadhesive Efficiency.
    Wang Q; Li C; Ren T; Chen S; Ye X; Guo H; He H; Zhang Y; Yin T; Liang XJ; Tang X
    Mol Pharm; 2017 Oct; 14(10):3598-3608. PubMed ID: 28892400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raloxifene encapsulated spanlastic nanogel for the prevention of bone fracture risk via transdermal administration: Pharmacokinetic and efficacy study in animal model.
    Ansari MD; Shafi S; Pandit J; Waheed A; Jahan RN; Khan I; Vohora D; Jain S; Aqil M; Sultana Y
    Drug Deliv Transl Res; 2024 Jun; 14(6):1635-1647. PubMed ID: 37996726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipomer of doxorubicin hydrochloride for enhanced oral bioavailability.
    Benival DM; Devarajan PV
    Int J Pharm; 2012 Feb; 423(2):554-61. PubMed ID: 22155412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and evaluation of solid lipid nanoparticles of raloxifene hydrochloride for enhanced bioavailability.
    Kushwaha AK; Vuddanda PR; Karunanidhi P; Singh SK; Singh S
    Biomed Res Int; 2013; 2013():584549. PubMed ID: 24228255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral bioavailability enhancement of raloxifene by developing microemulsion using D-optimal mixture design: optimization and in-vivo pharmacokinetic study.
    Shah N; Seth A; Balaraman R; Sailor G; Javia A; Gohil D
    Drug Dev Ind Pharm; 2018 Apr; 44(4):687-696. PubMed ID: 29168671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effective encapsulation of a hydrophobic lipid-insoluble drug in solid lipid nanoparticles using a modified double emulsion solvent evaporation method.
    Nabi-Meibodi M; Vatanara A; Najafabadi AR; Rouini MR; Ramezani V; Gilani K; Etemadzadeh SM; Azadmanesh K
    Colloids Surf B Biointerfaces; 2013 Dec; 112():408-14. PubMed ID: 24036624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chitosan and poly(methyl vinyl ether-co-maleic anhydride) microparticles as nasal sustained delivery systems.
    Cerchiara T; Luppi B; Chidichimo G; Bigucci F; Zecchi V
    Eur J Pharm Biopharm; 2005 Oct; 61(3):195-200. PubMed ID: 16006107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the cytotoxicity, genotoxicity and mucus permeation capacity of several surface modified poly(anhydride) nanoparticles designed for oral drug delivery.
    Iglesias T; López de Cerain A; Irache JM; Martín-Arbella N; Wilcox M; Pearson J; Azqueta A
    Int J Pharm; 2017 Jan; 517(1-2):67-79. PubMed ID: 27908629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atazanavir-loaded Eudragit RL 100 nanoparticles to improve oral bioavailability: optimization and in vitro/in vivo appraisal.
    Singh G; Pai RS
    Drug Deliv; 2016; 23(2):532-9. PubMed ID: 24963752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel biodegradable polyesters. Synthesis and application as drug carriers for the preparation of raloxifene HCl loaded nanoparticles.
    Bikiaris D; Karavelidis V; Karavas E
    Molecules; 2009 Jul; 14(7):2410-30. PubMed ID: 19633613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro/in-vivo characterization of trans-resveratrol-loaded nanoparticulate drug delivery system for oral administration.
    Singh G; Pai RS
    J Pharm Pharmacol; 2014 Aug; 66(8):1062-76. PubMed ID: 24779896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal delivery of raloxifene HCl via ethosomal system: Formulation, advanced characterizations and pharmacokinetic evaluation.
    Mahmood S; Mandal UK; Chatterjee B
    Int J Pharm; 2018 May; 542(1-2):36-46. PubMed ID: 29501737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In situ misemgel as a multifunctional dual-absorption platform for nasal delivery of raloxifene hydrochloride: formulation, characterization, and in vivo performance.
    Ahmed OA; Badr-Eldin SM
    Int J Nanomedicine; 2018; 13():6325-6335. PubMed ID: 30349253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.